Payment overview · 2025
General Payments
$14,814.71
36 reported records · 11 companies
Healthcare provider profile · identity verified
Arshdeep Tindni, M.D
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · CINCINNATI, OH · NPI 1023138401
Verified facts
What the public records show
CMS Open Payments records show Arshdeep Tindni, M.D received $14,814.71 in general payments during 2025 across 36 reported records.
AKEBIA THERAPEUTICS INC accounted for 96.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Veltassa.
AKEBIA THERAPEUTICS INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auryxia as an associated drug or biological on 494 records involving 327 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Auryxia by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 363 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veltassa as an associated drug or biological on 5970 records involving 2480 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Veltassa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14,246.96 | 96.2% | 22 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $208.38 | 1.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $96.05 | 0.7% | 1 | 2025 |
| Outset Medical Inc | Unresolved — no canonical attribution shown | $58.57 | 0.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $52.98 | 0.4% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $40.35 | 0.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.78 | 0.2% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $27.38 | 0.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.54 | 0.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.10 | 0.1% | 1 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.62 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,012.00 | 7 |
| Travel and Lodging | $1,569.02 | 4 |
| Food and Beverage | $1,142.79 | 24 |
| Education | $90.90 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $14,246.96 | 22 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $186.83 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $40.35 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.78 | 1 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| TERLIVAZ Normalized: terlivaz |
Drug | Mallinckrodt Hospital Products Inc. | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| PREVYMIS Normalized: prevymis |
Drug | Merck Sharp & Dohme LLC | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| Empaveli Normalized: empaveli |
Drug | Apellis Pharmaceuticals, Inc. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 363 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 42 | exact normalized | Medicare Part D |
| Veltassa veltassa |
2025 | Veltassa | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS INC Exact reporting entity; no affiliate inference |
2025 | Auryxia open payments reported associated product |
CMS Open Payments — General Payments 494 supporting records · 327 recipient NPIs · example record 1241812131 |
Auryxia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
363 | 115 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Vifor Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | Veltassa open payments reported associated product |
CMS Open Payments — General Payments 5970 supporting records · 2480 recipient NPIs · example record 1172020739 |
Veltassa · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 802 | 260 |
| Losartan Potassium | Losartan Potassium | 792 | 259 |
| Furosemide | Furosemide | 719 | 246 |
| Spironolactone | Spironolactone | 658 | 171 |
| Torsemide | Torsemide | 430 | 137 |
| Hydralazine Hcl | Hydralazine Hcl | 410 | 119 |
| Jardiance | Empagliflozin | 363 | 115 |
| Lisinopril | Lisinopril | 302 | 97 |
| Valsartan | Valsartan | 258 | 87 |
| Allopurinol | Allopurinol | 225 | 68 |
| Carvedilol | Carvedilol | 200 | 58 |
| Calcitriol | Calcitriol | 196 | 56 |
| Doxazosin Mesylate | Doxazosin Mesylate | 185 | 52 |
| Nifedipine Er | Nifedipine | 172 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 39 |
| Farxiga | Dapagliflozin Propanediol | 117 | 30 |
| Clinisol | Parenteral Amino Acid 15% No.5 | 105 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 98 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 30 |
| Atenolol | Atenolol | 85 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 29 |
| Clonidine Hcl | Clonidine Hcl | 80 | 26 |
| Finasteride | Finasteride | 79 | 21 |
| Eplerenone | Eplerenone | 78 | 18 |
| Atorvastatin Calcium | Atorvastatin Calcium | 71 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 70 | 22 |
| Calcium Acetate | Calcium Acetate | 69 | 31 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 65 | 15 |
| Potassium Chloride | Potassium Chloride | 63 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 18 |
| Prednisone | Prednisone | 56 | 25 |
| Sevelamer Carbonate | Sevelamer Carbonate | 54 | 25 |
| Lokelma | Sodium Zirconium Cyclosilicate | 53 | 15 |
| Famotidine | Famotidine | 52 | 15 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 50 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 17 |
| Midodrine Hcl | Midodrine Hcl | 46 | 11 |
| Metolazone | Metolazone | 44 | 23 |
| Potassium Citrate Er | Potassium Citrate | 44 | 14 |
| Omeprazole | Omeprazole | 43 | 16 |
| Kerendia | Finerenone | 42 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 13 |
| Irbesartan | Irbesartan | 40 | 11 |
| Cinacalcet Hcl | Cinacalcet Hcl | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 17 |
| Chlorthalidone | Chlorthalidone | 36 | 12 |
| Velphoro | Sucroferric Oxyhydroxide | 36 | suppressed |
| Klor-Con M20 | Potassium Chloride | 34 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 22 |
| Clonidine | Clonidine | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | 11 |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Metformin Hcl | Metformin Hcl | 22 | suppressed |
| Felodipine Er | Felodipine | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Gabapentin | Gabapentin | 17 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Auryxia | Ferric Citrate | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Prosol | Parenteral Amino Acid 20% No.1 | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14,814.71 · 36 records | AKEBIA THERAPEUTICS INC | ACTHAR, Empaveli, IBSRELA, JARDIANCE, Kerendia, PREVYMIS, TERLIVAZ, Vafseo, Veltassa | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AKEBIA THERAPEUTICS INC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error